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Introduction 
Well-designed biodegradable scaffolds in combination with bone growth factors offer a valuable 
alternative to the current gold standard autograft in spinal fusion surgery Yong et al. (2013). Here we 
report on 6- vs 12- month data set evaluating the longitudinal performance of a CaP coated 
polycaprolactone (PCL) scaffold loaded with recombinant human bone morphogenetic protein-2 
(rhBMP-2)  as a bone graft substitute within a large preclinical animal model. 
 
Methods 
Twelve sheep underwent a 3-level (T6/7, T8/9 and T10/11) discectomy with randomly allocated 
implantation of a different graft substitute at each of the three levels; (i) calcium phosphate (CaP) 
coated polycaprolactone based scaffold plus 0.54µg rhBMP-2, (ii) CaP coated PCL- based scaffold 
alone or (iii) autograft (mulched rib head). Fusion assessments were performed via high resolution 
clinical computed tomography and histological evaluation were undertaken at six (n=6) and twelve 
(n=6) months post-surgery using the Sucato grading system (Sucato et al. 2004). 
 
Results 
The computed tomography fusion grades of the 6- and 12- months in the rhBMP-2 plus PCL- based 
scaffold group were 1.9 and 2.1 respectively, in the autograft group 1.9 and 1.3 respectively, and in 
the scaffold alone group 0.9 and 1.17 respectively. There were no statistically significant differences 
in the fusion scores between 6- and 12- month for the rhBMP plus PCL- based scaffold or PCL – 
based scaffold alone group however there was a significant reduction in scores in the autograft group. 
These scores were seen to correlate with histological evaluations of the respective groups.  
 
Conclusions 
The results of this study demonstrate the efficacy of scaffold-based delivery of rhBMP-2 in promoting 
higher fusion grades at 6- and 12- months in comparison to the scaffold alone or autograft group 
within the same time frame. Fusion grades achieved at six months using PCL+rhBMP-2 are not 
significantly increased at twelve months post-surgery. 
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